Hanneke I. Vos

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

Dagmar Berghuis, Marco W. Schilham, Hanneke I. Vos et al. · Clinical Sarcoma Research · 2012 · 65 citations · Full text

Medicine, Immunology, Oncology +17

Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma

Hanneke I. Vos, Henk‐Jan Guchelaar, Hans Gelderblom et al. · Pharmacogenetics and Genomics · 2016 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Melanie M. Hagleitner, Marieke J. H. Coenen, Hans Gelderblom et al. · Clinical Cancer Research · 2015 · 45 citations

Medicine, Genetics, Oncology +17

High-Quality Genotyping Data from Formalin-Fixed, Paraffin-Embedded Tissue on the Drug Metabolizing Enzymes and Transporters Plus Array

Hanneke I. Vos, Tahar van der Straaten, Marieke J. H. Coenen et al. · Journal of Molecular Diagnostics · 2014 · 13 citations · Full text

Medicine, Biochemistry, Molecular Medicine +15